Category: ACN Newswire

SINGAPORE, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - In today's fast-paced world, many individuals find themselves grappling with overwhelming stress and its accompanying challenges. The constant pressures of modern life can leave individuals feeling mentally and physically drained.Especially in Singapore, the hustle culture and rising cost of living contributes heavily to this. A recent survey found that nearly 90% of Singaporeans experience chronic stress, driven by issues like financial concerns and a general uncertainty about the future. This relentless pace, paired with the constant pressure to meet expectations, continues to take a toll on both mental and physical health, even as the new year begins.Prolonged stress can, however, impact cognitive functions leading to brain fog, memory loss and inflammation, while the digestive system may struggle to keep up with the demands of life. When the mind is overloaded, it becomes difficult to focus, make decisions, or retain information, leading to decreased productivity and increased frustracalention. Furthermore, prolonged stress can disrupt the gut-brain connection, triggering digestive issues such as bloating, indigestion, and inflammation, which hinder the body’s ability to absorb essential nutrients.LAC (pronounced as L-A-C) aims to help individuals navigate these transitions with mindful practices and targeted health solutions. For individuals grappling with cognitive or digestive issues, LAC recommends its BrainSpeed® PS and Probiotic Complex 25 Billion CFU - Daily Support to help support mental and digestive health.Formulated with high phosphatidylserine (PS), LAC BrainSpeed® PS promotes brain health, enhances focus and alertness, and helps individuals cope with stress more effectively, resulting in overall work productivity. This supplement helps to regulate high stress levels, balances mood and promotes cognitive functions for individuals who are seeking mental clarity.With over 25 Billion CFUs of active probiotics and 12 strains of friendly bacteria, Probiotic Complex 25 Billion CFU - Daily Support helps to effectively maintain probiotic levels and boosts the immune system, reducing the risks of inflammation in the gut, maintaining a healthy balance of bacteria in the body.LAC also offers solutions for children to support optimal health and overall well-being. LAC BrainSpeed® Junior is specially formulated with DHA to support cognitive development and mental clarity, allowing children to stay focused in their schools. On the other hand, LAC Probiotic Junior contains 12.5 Billion CFU of Probiotics that strengthens the immune system and absorbs essential nutrients effectively.You may access the high-resolution visuals of the products through the media kit here. Copyright 2025 ACN Newswire via SeaPRwire.com.

- HuaTangNing completed its first full year for reimbursement under the National Reimbursement Drug List (NRDL), with continued expansion in hospital coverage. Compared with the 2023 year, sales volume increased by approximately 740%.- Sales revenue increased by 234% compared with the 2023 year, with cash reserves exceeding RMB 1 billion to fully support future R&D and commercialization activities.- A Phase I clinical study of our second-generation GKA, a once daily oral therapy, successfully completed in the United States. Our dorzagliatin-metformin fixed-dose combination formulation progressed smoothly and our product pipeline continued to advance and expand.- The Mendelian Randomization studies of human genetic data provided scientific evidence to support the exploration of glucokinase activation in diabetic complications and new clinical indications.- Manufacturing capacity of dorzagliatin continued to expand to meet growing market demand.- The establishment of Hua Medicine’s pharmaceutical sales and marketing team resulted in significant sales growth in the first two months of 2025, opening a new model of innovative drug commercialization.SHANGHAI, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the “Reporting Period”), along with the Company’s business progress in 2024 and future business outlook. Hua Medicine has made significant strides in the commercialization of its core product, the glucokinase activator (GKA) dorzagliatin (trade name: HuaTangNing, as well as in R&D innovation and manufacturing capacity optimization, laying a solid foundation for the Company’s long-term sustainable development.Dr. Li Chen, Founder and the Chief Executive Officer of Hua Medicine, stated: “In 2024, HuaTangNing’s market performance was very encouraging. Its inclusion in the NRDL greatly enhanced the accessibility and affordability of this innovative drug, enabling more diabetes patients to benefit. In 2025, Hua Medicine established a pharmaceutical sales and marketing team, and HuaTangNing demonstrated strong growth momentum at the start of the year. With further market expansion and increasing patient awareness, we are confident in HuaTangNing’s market growth.”“Looking ahead, the Company will continue to explore HuaTangNing’s potential in personalized diabetes treatment and diabetes complications globally. By integrating big data and artificial intelligence technologies, we aim to expand our disease areas into immune homeostasis and neural homeostasis. We are confident with the close collaboration of Hua Medicine and its partners across the pharmaceutical R&D, production, and distribution chain, we can enable more patients to access and benefit from Chinese medicines, accelerating progress in realizing our vision ‘China leading pharmaceutical innovation to advance human health.’”Summary of Clinical Research and Operational Progress- Significant Revenue Growth, Strong Market Performance of HuaTangNing, and Positive Patient Feedback- 2024 marked the first full year for which our HuaTangNing was reimbursed under the National Reimbursement Drug List (“NRDL”) in China. Sales revenue increased by 234% to RMB255.9 million for the fiscal year 2024 compared with the same period in 2023. During the fiscal year 2024, HuaTangNing was sold in approximately 2,700 hospitals across China. As of December 31, 2024, Hua Medicine maintained a strong balance sheet with a cash balance of RMB1,139.8 million to support its full-scale commercialization, business development and R&D functions.- Since the launch of HuaTangNing in the fourth quarter of 2022, our pharmacovigilance team has been diligently monitoring the safety of dorzagliatin in the China market, and was recently recognized by the National Adverse Drug Reaction Monitoring Center as a national example for the pharmaceutical industry. As of December 31, 2024, Hua Medicine had monitored approximately 150,000 patients who have been prescribed HuaTangNing, and dorzagliatin has been observed to be safe and well tolerated by patients.- Effective January 1, 2025, Hua Medicine assumed full responsibility for the commercialization of HuaTangNing in China from its former sales and marketing partner, Bayer Healthcare Company Limited (“Bayer”). We recruited Mr. Lu Yu, a seasoned pharmaceutical sales executive with over 20 years of diabetes commercialization experience in China, to lead our sales and marketing efforts.- For the two months ended February 28, 2025, Hua Medicine sold approximately 592,000 packs of HuaTangNing, representing approximately RMB73.2 million in net sales. During the same period in 2024, approximately 202,000 packs of HuaTangNing were sold, representing approximately RMB24.5 million in net sales, The difference represents a significant increase in sales over a period during which the price per pack remained the same. This demonstrates a smooth transition of HuaTangNing’s commercialization in China from Bayer to Hua Medicine, with reinvigorated growth momentum.- Upon the termination of the Exclusive Promotion Service Agreement, the unamortized contact liabilities amounting to RMB1,243,499,000 were released to profit or loss, and will be recognized as a gain in 2025 by the Group. Both parties have confirmed in a signed letter that there are no outstanding matters arising from such termination, nor does either party owe the other party any obligation or liabilities from such separation.- Steady Progress in R&D Innovation, Continuously Enriching Product Pipeline- Hua Medicine made significant headway in preparing the future expansion of our glucokinase-targeted, glucose homeostasis-centered therapy into the international markets, specifically the United States. We successfully completed and announced the results of its single-ascending dose (“SAD”) study in the United States of our second generation GKA (HM-002-1005), in which we validated the feasibility of dorzagliatin as a once daily oral therapy for Type 2 diabetes (“T2D”) patients. We are currently developing the clinical dosage form for advancement of HM-002-1005 in a clinical proof-of-mechanism study.- Hua Medicine also made significant progress in developing fixed-dose combination formulations. The Company has been advancing its dorzagliatin-metformin fixed-dose combination product candidate into commercial dosage development, with process validation expected to be completed in 2025.- Based on human genetic data collected from studies of patients administered with dorzagliatin, the Mendelian Randomization methodology has been applied to predict the beneficial effects of dorzagliatin on related and significant diabetes complications, such as reduction in heart failure, coronary artery disease, memory loss and dyslipidemia. In addition, a separate Mendelian Randomization study provided genetic evidence supporting the causal effects of glucokinase activation on lowering the risk of frailty. These findings suggest that glucokinase activators may aid in the management of frailty and sarcopaenia in people with diabetes. We will continue our research and development efforts to explore new indications.- Through our SENSITIZE 3 clinical study in Hong Kong, Hua Medicine is advancing the potential of dorzagliatin in prediabetes, early treatment and prevention of Type 2 diabetes. In contrast with the approved 75mg dosage form of HuaTangNing, the Company is testing new 25mg and 50mg dosage formulations to explore these potential new indications. The Company is also supporting an investigator-sponsored trial in testing dorzagliatin’s efficacy in treating MODY-2 patients who suffered from genetic mutations that de-activated glucokinase. Early studies in humans by renowned diabetes experts Dr. Juliana Chan and Dr. Linong Ji have indicated the benefit of dorzagliatin in MODY-2 patients by improving their β-cell functions and glycemic control.- Hua Medicine is also advancing the combination of dorzagliatin with GLP-1RA, DPP-IV inhibitors and SGLT-2 inhibitor through combined effects in collecting real-world evidence and proof-of-concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indication into other diseases in metabolic disorders, such as obesity and MASH. - Hua Medicine will continue our engagement in diabetes prevention, opportunities in longevity and prevention of memory loss and eventually find a new way to increase healthy life span and longevity in humans.- Continued Expansion of Manufacturing Capacity, Plans to Launch Dorzagliatin in New Markets- Hua Medicine continues to invest in expanding its manufacturing capacity to meet anticipated market needs in 2026 and 2027.- Hua Medicine is also finalizing and preparing to submit registration applications for dorzagliatin to launch commercialization in the Macau and Hong Kong markets. We plan to submit both applications in 2025.- Hua Medicine continues to strengthen its intellectual property protection globally. As of December 31, 2024, the Company owned more than 200 granted patents covering its proprietary technology worldwide.Business outlook- There is a great opportunity for dorzagliatin and our 2nd generation GKA in China and the global oral anti-diabetes market. - We will strengthen our own commercialization efforts through hub and spoke development with focus on building up a strong internal sales and medical marketing organization to drive business growth in 2025. This will allow us to rebuild our strong connections directly to the medical community and better promote HuaTangNing in China and surrounding areas.- We continue to invest into digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.- We are working on the registration of dorzagliatin in HK and Macau region and engage partnerships in Southeastern Asia and Belt and Road nations. In addition, business development work on our 2nd generation GKA in regions with high incidences of obesity will be continued based on the initial success of the SAD study in the United States.Financial SummaryFor the year ended December 31, 2024:- Bank balances and cash position was approximately RMB1,139.8 million.- Total revenue was approximately RMB255.9 million, an increase of approximately 234% compared to the full year of 2023; approximately 2,105,000 packs of HuaTangNing were sold, an increase of approximately 740% compared to the full year of 2023.- Total other income was approximately RMB116.8 million, including approximately RMB95.7 million from the amortization of Bayer milestone income.- Total expenditures for the year was approximately RMB493.6 million, of which R&D expenses accounted for approximately RMB215.1 million.- Loss before tax was approximately RMB250.1 million, which was mainly attributable to the increase of selling expense and research and development expense.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more information Hua MedicineWebsite:www.huamedicine.comInvestorsEmail:ir@huamedicine.comMediaEmail:pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Mar 28, 2025 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2024 (the “Year” or “FY2024”).Financial Highlights- Contracts-in-hand remained at a high level of HK$11,052.7 million- Revenue rose to HK$6,450.1 million, up 5.2% year-on-year- Adjusted profit attributable to owners of the company recorded HK$206.0 million 1 with a growth of 10.2% 2 year-on-year, excluding a one-off expense and provision- Total dividend for the year amounted to HK4.38 cents per shareChairman Dr Mak Kin Wah said, “Capturing opportunities from shifting market priorities towards intelligent and digital solutions, data centres, environmental engineering and climate solutions, hospitals, infrastructure, and housing, we maintained a high level of contracts-in-hand across the Group’s diverse scope of business, providing a strong underlying foundation for the business over the next two years and beyond; this was notwithstanding the challenges around the world and in Hong Kong during the year.ATAL Tower, our new headquarters, is a significant investment that demonstrates our confidence in the future and our commitment to Hong Kong. We will continue to leverage our expertise and strong financial position to take up additional opportunities in the Hong Kong market, and explore further business development in overseas markets. Our investment in research and development, and innovation will enhance our core strengths and competitiveness. We will tirelessly live up to our motto of ‘We Commit. We Perform. We Deliver.’, ultimately driving our sustainable growth, optimising value for shareholders and other stakeholders, and contributing to the wider community.”Business Review: Building Services- This segment is the largest revenue contributor, with revenue up 5.3% to HK$3,933 million.- The recurring maintenance revenue increased by 40.2% to HK$422 million.- Leadership in the innovative construction technology of Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) received a major boost during the year, not only with the award of significant contract for a Grade A office building in Causeway Bay with the highest level of MiMEP application at 85% for a commercial building, but also with the development of our own systematic MiMEP methodologies and solutions.- The “MiMEP Design and Manufacturing Centre” and “MiMEP High Productivity Research Centre” in Zhuhai, as well as other MiMEP manufacturing facilities in Hong Kong, were established to integrate our capabilities in the Greater Bay Area with cutting-edge technology from Hong Kong.Environmental Engineering- The order intake significantly increased by 107.4% to HK$1,514 million, with contracts won for environmental infrastructure needed to enhance climate resilience, environmental protection, sustainability of water supply and waste treatment, and support for public housing and utilities.- The segment actively extended its expert services around the world, including Teresa in the Philippines, Dubai and other parts of the world.Information, Communications and Building Technologies (“ICBT”)- The order intake increased 22.5% to HK$757 million, with contracts-in-hand up 13.8% to HK$959 million.- The segment actively collaborated with leading manufacturers worldwide and in Mainland China to expand its technology reach and deliver cutting-edge solutions in diverse sectors.Lifts and Escalators- There was a significant growth in order intake and revenue, up 48.5% to HK$548 million and up 39.9% to HK$529 million respectively.- The two recently acquired lift companies in the United Kingdom (“UK”) contributed to revenue growth and made progress in the UK business.- The associate in the United States turned from a loss to a profit in FY2024 and made progress in expanding its business into additional cities in the South.For further details of the 2024 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.Remark:1. Profit attributable to the owners of the Company was HK$135.3 million, including a one-off expense of approximately HK$23.1 million before tax for relocation to the new consolidated headquarters to realise enhanced efficiency and synergy across business units, and a provision for expected credit loss of HK$88.0 million before tax to reflect risks with the recoverability of certain receivables and contract assets held by the Group in relation to certain construction companies.2. When compared with the adjusted profit attributable to owners of the company of HK$186.9 million in FY2023, which excludes a one-off dilution gain before tax upon completion of a private placement by an associate in Mainland China, a gain on disposal of interest before tax in an associate, and a provision before tax in respect of certain contracts in the healthcare sector.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司（「安樂工程」或「公司」，連同附屬公司統稱（「集團」））（股份代號：1977），今天宣佈截至2024年12月31日止年度（「年內」或「2024財政年度」）的全年業績。財務摘要- 手頭合約總值維持在110.527億港元高位- 收益上升至64.501億港元，按年增加5.2%- 扣除一次性開支及撥備，經調整本公司擁有人應佔溢利為2.06億港元1，按年增加10.2%2- 全年合共派息每股4.38港仙主席麥建華博士表示：「儘管年內全球及香港面臨挑戰，我們憑藉多元化的業務範疇，把握轉趨於智能及數碼解決方案、數據中心、環境工程和氣候解決方案、醫院、基建和房屋等市場機遇，使手頭合約維持高位，為未來兩年及未來的業務發展奠定穩固的基礎。」「新總部安樂工程大廈的啟用，不僅是集團對未來發展的重要投資，亦彰顯我們對香港前景信心滿滿。我們將繼續發揮專業知識和財務優勢，把握更多香港市場的機會，並拓展海外市場的新業務發展。持續投資於研發和創新將增強我們的核心優勢和競爭力。我們將貫切實踐『重承諾、慎履行、獻成果』的座右銘，推動可持續增長，最終為股東和其他持份者創造最佳價值，貢獻社會。」業務回顧：屋宇裝備工程- 該業務板塊對集團的收益貢獻最大，收益上升5.3%，達39.33億港元。- 經常性維修保養收益增加40.2%至4.22億港元。- 在創新建築技術 - 機電裝備合成法（「MiMEP」）的業界領導地位於年內獲得進一步提升，不僅獲得重大合約，為銅鑼灣一幢甲級辦公大樓應用MiMEP達85%，屬商業樓宇的最高水平，更自主研發系統化的MiMEP指引及解決方案。- 在珠海設立「機電裝備合成法設計及建造中心」和「機電裝備合成法高效生產研發中心」，以及於香港設立相關的MiMEP生產設施，旨在將我們於大灣區的生產力與香港的尖端技術相結合。環境工程- 訂單額大幅增長107.4%至15.14億港元，主要由於贏得的合約涉及加強氣候適應力、環境保護、供水及廢物處理的可持續性，以及支持公共房屋及公用事業所需的環境基建。- 積極將其優質服務擴展至全球，包括菲律賓特蕾莎(Teresa)、杜拜及全球其他地區。資訊、通訊及屋宇科技（「ICBT」）- 訂單額增加22.5%至7.57億港元，手頭合約價值上升13.8%至9.59億港元。- 積極與全球及中國內地的領先生產商合作，以擴大技術應用範疇，並為不同領域提供先進技術的解決方案。升降機及自動梯- 訂單額和收益均獲得顯著的增長，分別提升48.5%至5.48億港元和39.9%至5.29億港元。- 近年收購的兩家英國升降機公司對收益增長作出貢獻，並推動英國業務取得進展。- 美國聯營公司於2024財政年度實現轉虧為盈，並將業務進一步擴展至美國南部其他城市。有關2024年度業績詳情，請參閱已呈交香港聯合交易所有限公司的公告。註：1.本公司擁有人應佔溢利為1.353億港元，當中包括因搬遷至新綜合總部以增強業務部門之間的效率及協同效應而產生一次性稅前開支約2,310萬港元，以及預期信貸虧損的稅前撥備8,800萬港元，以反映與若干建築公司有關的應收款項及合約資產可收回性的風險。2.比較2023財政年度經調整本公司擁有人應佔溢利1.869億港元（已撇除一間中國內地聯營公司完成私人配售後一次性稅前攤薄收益、出售於聯營公司權益的稅前收益及就若干醫療保健業務合約的稅前撥備）。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年，為領先的機電工程與智慧城市的資訊及通訊科技服務供應商，總部設於香港，業務遍及澳門、中國內地、美國及英國。本集團為不同行業，包括公共和私營的客戶提供跨專業、綜合性的機電工程和技術服務，涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技（「ICBT」），以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售Anlev升降機及自動梯，並與美國紐約最大獨立升降機及自動梯公司之一Transel Elevator & Electric Inc.（「TEI」）達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司（603912.SS）專門製造精密空調設備。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Mar 29, 2025 - (ACN Newswire via SeaPRwire.com) - Mobvoi (02438.HK) (hereinafter referred to as “the Group”) released its 2024 annual results report. The Group's pure software product, AIGC, generated a revenue of over RMB220 million (unit: RMB, the same below), representing a year-on-year growth of 88.5% compared with 2023, and has truly achieved pure software, high gross profit and internationalization.In terms of total revenue, for the year ended December 31, 2024, the Group's revenue amounted to RMB390.3 million, representing an increase of 6% as compared to the corresponding period in 2023 (after deducting the revenue from the IP arrangement of Automobile Subsidiary A). Of which, revenue from AIGC solutions amounted to RMB221.7 million, revenue from AI solutions amounted to RMB16.4 million and revenue from smart devices and other accessories amounted to RMB152.2 million.Pure Software Product AIGC Revenue Exceeds RMB220 Million, Realizing Sustainable Growth of AIGC Business ModelAs the Group's core business, the AIGC business has maintained strong growth in recent years. This is attributable to the Group's proactive adjustment of its business and revenue strategy away from increasing traditional AI project-based revenue (such as the business of Automobile Subsidiary A) and fully engaging in the sustainable growth of pure software AIGC productization business. For the years ending December 31, 2021, 2022, 2023 and 2024, AIGC revenue amounted to RMB6.8 million, RMB39.9 million, RMB117.6 million and RMB221.7 million respectively, accounting for 1.7%, 8.0%, 23.3% and 56.8% of the Group's total revenue respectively. It is worth mentioning that the Group's AIGC business grew by 88.5% year-on-year compared to 2023, truly achieving pure software, high margins and internationalization, and the Group has become the “No. 1 AIGC Company”.The growth of the AIGC business is attributable to the Group's pioneering technologies and the increasingly rich application of AIGC products. 2024 saw the Group's continuous efforts in the areas of AI intelligences, big models and digital people, and the formation of a complete matrix of AIGC products: AI dubbing assistant “Moyin Workshop” (the overseas version of “DupDub”), AI digital human doppelganger “Weta365” (the overseas version of “LivGen”), an enterprise AI interactive digital employee generation platform “AI Ask365”, and an AI video creation platform “Yuan365”, etc.Meanwhile, with business refinement, operational capability and brand influence further enhanced. As of December 31, 2024, the Group's AIGC will have more than 10 million registered users and more than 1 million paid users, and will continue to provide services to users from China, North America, Europe, Southeast Asia and other parts of the world.Adhering to the strategy of “product and model integration”, constantly breaking through the boundary of innovation“Product and model integration” has enabled AI application companies to increase their modeling capabilities. The Group is one of those companies that have taken “product and model integration” as a strategic guideline to build data and product barriers on the basis of advanced models (such as “Sequence Monkey” and DeepSeek).On the one hand, “product and model integration” can greatly improve efficiency, self-developed models can quickly respond to their own product needs, cost savings, private customization; on the other hand, the “data flywheel” effect can be formed, through the data to promote the product and the model of the dual self-iterative.From the model level, the Group insisted on model capability iterations in 2024, leading industry breakthroughs in AI intelligences, voice, digital people, video and images.For example, the Group has continuously upgraded the technology of its voice model engine, which has now been iterated to the seventh generation (TicVoice 7.0), and after applying it to “Moyin Workshop” and “DupDub”, not only does the product have supernatural voice cloning and cross-language generation capabilities, but also can be customized to meet the needs of users with boutique-exclusive voices.In the field of digital human, the Group released WetaAvatar 4.0, AI video dubbing and WetaAvatar 4.0 Talking Photo in 2024, which further upgraded Weta365's capabilities. “The case video of Weta365's cooperation with Yiwu Small Commodities once dominated New York's Times Square. In the future, both parties will bring better technical services to over 65,000 small merchants, truly enabling business without boundaries.In the area of AI intelligent bodies, the Group has continued to make in-depth efforts in the area of AI Agent and has landed a product that integrates big model, embodied intelligence and AI Agent, “Xiaoqian Mobile Digital Man”. It has a flexible and mobile body that can realize intelligent following, self-defined route cruising and intelligent obstacle avoidance. At the same time, it is equipped with leading models such as ““Sequence Monkey”” and “DeepSeek” to realize intelligent Q&A.In the future, the Group will continue to adhere to the core strategic anchor of “product and model integration” and promote the deep integration of technology and scenarios, so as to become a global benchmark practitioner of synergistic innovation between products and models.Continuing to build overseas products and focusing on globalized ecological layoutThe Group has a strong overseas gene and has accumulated valuable global business development experience, sales team and media resources during the early years of its hardware overseas products.In 2024, on the one hand, the Group upgraded its overseas AI dubbing product “DupDub”, which was highly recognized by creators from around the world. On the other hand, the Group launched “LivGen”, a one-stop digital human generation platform, which not only brings the ultimate creative experience to creators, but also helps enterprises build “24-hour AI staff without borders” with its rich digital human images and multilingual advantages, thereby realizing cost reduction and efficiency enhancement.In addition to building global products, the Group also focuses on global ecological deployment, and has become partners with international companies such as NVIDIA, Google, Qualcomm, DingTalk, Hicloud and Tencent Cloud to help the industry's ecological development.Fully embrace the AIization of organizations and be the forerunner of the smart business eraThe Group believes that “Organizational AI” will become the core path of enterprise evolution. In this regard, the Group will continue to promote the dual leap of organizational and product AI.Relying on its own technology, the Group will allow AI to penetrate into the operation and management of the organization through data infrastructure, the establishment of Agent workflow, and organizational transformation, so as to enhance the collaboration between AI and human beings, and allow AI to promote the innovation of production relationship and exponentially increase productivity.Looking ahead, the Group will build an AGI-driven future with its “product and model integration” strategy, a healthy and sustainable business model, and an open global ecosystem that anchors long-term value. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月29日 - (亞太商訊 via SeaPRwire.com) - 出門問問（02438.HK）（以下簡稱「集團」）發佈2024年度業績報告。集團AIGC純軟件產品營收超2.2億元（單位：人民幣，下同），較2023年同比增長88.5%，真正做到了純軟件、高毛利與國際化。總收入方面，截至2024年12月31日止年度，集團的收入為人民幣390.3百萬元，與2023年同期相比增長6%（扣除汽車附屬公司A的知識產權安排收入）。其中AIGC解決方案收入為人民幣221.7百萬元，AI解決方案收入為人民幣16.4百萬元，智能設備及其他配件收入為人民幣152.2百萬元。AIGC純軟件產品營收超2.2億，實現可持續增長的AIGC業務模式作為集團的核心業務，AIGC業務近年來保持着強勁的增長。這得益於集團積極調整業務及收入戰略，不再增加傳統AI項目制收入（例如汽車附屬公司A的業務），全面投身於可持續增長的純軟件AIGC產品化業務。截至2021年、2022年、2023年及2024年12月31日止年度，AIGC營收分別為人民幣6.8百萬元、39.9百萬元、117.6百萬元、221.7百萬元，占集團總收入的比例分別是1.7%、8.0%、23.3%及56.8%。值得一提的是，與2023年相比，集團的AIGC業務同比增長88.5%，真正做到了純軟件、高毛利、國際化，集團已成為名副其實的「AIGC第一股」。AIGC業務的增長離不開集團領先行業的技術與日益豐富的AIGC產品應用。2024年，集團在AI 智能體、大模型、數字人等領域持續發力，並形成了完整的AIGC產品矩陣：AI配音助手「魔音工坊」（海外版 DupDub）、AI數字人分身「奇妙元」（海外版「LivGen」）、企業AI交互式數字員工生成平台「奇妙問」、AI視頻創作平台「元創島」等。同時，隨着業務精進、運營能力和品牌影響力的進一步提升。截至2024年12月31日，集團的AIGC註冊用戶數量超 1000萬人，付費用戶數量超100萬人，持續為來自中國、北美、歐洲、東南亞等全球用戶提供服務。堅持「產模結合」的戰略，不斷突破創新邊界「產模結合」讓AI應用公司隨模型能力「水漲船高」。本集團正是這種將「產模結合」作為戰略指引的公司，能在先進模型（如序列猴子、DeepSeek等）的基礎上構建數據壁壘、產品壁壘。一方面，「產模結合」可以大幅提高效率，自研模型可以快速響應自身產品需求、節省成本、私有化定製；另一方面是可形成「數據飛輪」效應，可以通過數據推動產品和模型雙重自我迭代。從模型層面來看，2024年集團堅持進行模型能力迭代，在AI智能體、語音、數字人、視頻和圖像等領銜行業突破。例如，集團不斷對語音大模型引擎進行技術升級，目前已迭代至第七代（TicVoice 7.0），將其應用於「魔音工坊」「DupDub」後，不僅讓產品具備超自然的語音克隆與跨語種生成能力，還可根據用戶需求定製精品專屬聲音。數字人領域，集團在2024年發佈了WetaAvatar 4.0、AI視頻配音、WetaAvatar 4.0 Talking Photo等，使得「奇妙元」的能力再度升級。「奇妙元」攜手義烏小商品的合作的案例視頻一度霸屏紐約時代廣場，未來雙方將為超過6.5萬小戶商家帶來更好的技術服務，真正做到讓商業無邊界。AI智能體領域，集團在AI Agent領域持續深耕，並落地了一款集大模型、具身智能、AI Agent於一體的產品「小問移動數字人」。它擁有靈活移動的身體，可以實現智能跟隨、自定義路線巡航及智能避障。同時，它也搭載了「序列猴子」「DeepSeek」等領先大模型，實現智能問答。未來，集團也將繼續堅定「產模結合」的核心戰略錨點，推動技術與場景的深度融合迭代，成為全球產模協同創新的標杆實踐者。持續打造出海產品，專注全球化生態佈局集團擁有深厚的出海基因，在早年的硬件出海產品過程中積累了寶貴的全球化業務發展經驗、銷售團隊與媒體資源。2024年，一方面，集團對海外AI配音產品「DupDub」不斷升級，獲得了來自全球創作者的高度認可。另一方面，集團推出了一站式數字人生成平台「LivGen」，不僅可以為創作者帶來極致的創作體驗，也可以用豐富的數字人形象、多國語言優勢幫助企業構建「24小時AI無國界員工」，實現降本增效。除了打造全球化的產品，集團也專注於進行全球化的生態佈局，先後與NVIDIA、Google、高通、釘釘、華為雲、騰訊雲等國際化公司成為合作夥伴，助力行業生態發展。全面擁抱組織AI化，做智能商業時代的先行者集團認為「組織AI化」將成為企業進化的核心路徑，為此，集團將持續推動組織與產品AI化的雙重躍遷。依託自有技術，集團將通過數據基建、建立Agent工作流、組織轉型等方式，讓AI滲透組織運營與管理之中，增強AI與人的協作，讓AI促進生產關係的革新，指數級提升生產力。放眼未來，集團將以「產模結合」的戰略、健康可持續的商業模式、全球生態的開放格局，錨定長期價值，打造一個由AGI驅動的未來。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月29日 - (亞太商訊 via SeaPRwire.com) - 廣發証券股份有限公司（「廣發証券」或「公司」，公司及併表範圍內的子公司〔附屬公司〕，統稱「集團」）發佈2024年度報告。過去一年，是我國經濟轉型、資本市場全面深化改革的關鍵一年，面對充滿挑戰的宏觀形勢與深刻變化的行業格局，廣發証券堅守「功能性」定位，切實發揮服務實體經濟的作用，各項工作穩中向好，主要經營指標位居行業前列，全年實現收入及其他收益總額人民幣373.46億元，歸屬于本公司股東的淨利潤人民幣96.37億元。作為國內首批大型綜合類券商，廣發証券擁有投資銀行、財富管理、交易及機構和投資管理四大業務板塊，具備全業務牌照；先後設立期貨子公司、公募基金子公司、私募基金子公司、另類投資子公司和資產管理子公司等，以獨有的價值理念和務實的創業作風，打造了佈局完善、實力強勁的全業務鏈條。在區域發展上，公司立足廣東，服務全國，聯通境內外，以長遠的眼光、開放的格局鍛造綜合金融服務實力，主要經營指標連續多年穩居中國券商前列。廣發証券董事長林傳輝表示，過去的一年，公司堅守服務實體經濟初心，回歸行業本源謀發展；主動融入國家發展大局，深耕「五篇大文章」展現新作為。2025年，資本市場「1+N政策」將持續落地走實，投資價值進一步凸顯。公司將堅守主責主業，把發揮功能性放在首要位置，在擁抱科技革命中積極創新變革，努力為資本市場高品質發展貢獻廣發力量。聚焦主責主業 四大業務板塊穩健增長廣發証券擁有完備的業務體系、均衡的業務結構，在財富管理、資產管理、研究等多項核心業務領域中形成領先優勢。報告期內，公司四大業務板塊均實現穩健增長。財富管理轉型成效顯著。截至2024年末，公司代銷金融產品保有規模超過2,600億元，較上年末增長約22%；滬深股票基金成交額達23.95萬億元（雙邊統計），同比增長28.98%；融資融券餘額突破1,036.86億元，同比增長16.52%，市場份額達5.56%，客戶資產配置需求持續釋放。擁有投資顧問團隊超4,600人，蟬聯行業第一（母公司口徑）。境外金融產品銷售淨收入、保有量及多市場交易傭金均實現同比增長。投行業務實現逆週期增長。報告期內，公司股債承銷規模均進入行業前十。在股權融資方面，公司完成A股股權融資主承銷金額86.66億元，市場份額逆勢提升；同時境外投行完成14單港股IPO及1單美股IPO，根據Dealogic統計，按IPO和再融資專案發行總規模在所有承銷商中平均分配的口徑計算，在香港市場股權融資業務排名中資證券公司第4。債務融資方面，公司主承銷發行債券665期，同比增長59.86%；主承銷金額2,963.22億元，同比增長21.22%。在中資境外債業務方面，完成60單債券發行，承銷金額110.22億美元。並購重組業務主導完成5單境內重大交易，涉及金額133.57億元。投資管理板塊優勢鞏固。集團旗下控股子公司廣發基金和參股子公司易方達基金合計管理公募基金規模超過3.5萬億元，剔除貨幣市場型基金後的規模分別排名行業第3、第1（資料來源：Wind，公司統計）。全資私募基金子公司廣發信德聚焦佈局生物醫藥、智能製造、新能源、企業服務等行業，2024年三季度管理基金月均實繳規模超過175億元（資料來源：中國證券投資基金業協會）。在境外，集團間接全資持股的子公司廣發投資（香港）聚焦高端製造、TMT、大消費、生物醫療等核心領域進行投資佈局，部分項目已成功通過並購退出或在香港、美國等證券交易所上市。交易及機構業務板塊持續發力。作為場外衍生品業務一級交易商，公司交易業務穩居第一梯隊，為上交所、深交所的800餘檔基金及全部ETF期權提供做市服務，為中金所的滬深300股指期權、中證1000股指期權提供做市服務，為43家新三板企業提供做市服務。報告期內，公司通過中證機構間報價系統和櫃台市場發行私募產品84,691只，合計規模人民幣9,007.44億元；FICC業務多策略規模持續增長；公募基金託管存續規模排名行業第5。以客戶為中心 錘煉綜合金融服務能力廣發証券堅持以投資者為本，通過錘煉全業務鏈、全生命週期的綜合金融服務能力，持續提升對個人投資者、機構客戶、企業客戶等不同客群的服務質效，並以良好的發展成果回饋投資者。針對個人投資者，公司始終踐行「以客戶為中心」的經營理念，堅定不移地加快向買方投顧轉型，與投資者利益保持高度一致。報告期內，公司緊跟高品質發展主基調和數字化、平台化戰略，聚焦財富經紀業務「高品質客群和高效率線上運營」重點發展方向，線上線下並舉，做好客戶服務和運營，財富經紀業務轉型改革逐步落地見效，服務居民財富管理的綜合能力持續增強，公司代銷非貨幣公募基金保有規模行業排名穩居第三。截至2024年12月末，公司擁有全國356家分公司及營業部，實現全國31個省、直轄市、自治區全覆蓋；其中，粵港澳大灣區珠三角九市營業網點家數及覆蓋佔比均為行業第一，為公司業務開展提供了廣泛的市場觸角，為客戶積累和服務提供重要支撐。2024年，公司還獲得首批跨境理財通業務試點資格，在深化粵港澳大灣區金融合作、助力居民財富跨境配置方面又邁出了堅實的一步。在機構客戶服務方面，公司卓越的研究能力在業界享有盛譽，屢獲殊榮，連續多年榮獲證券時報最佳分析師、新財富最佳分析師、中國證券業分析師金牛獎等主流評選的機構大獎，並名列前茅。截至2024年12月末，公司的股票研究涵蓋境內28個行業的993家A股上市公司，以及在香港或海外上市的169家公司。2024年，圍繞中國式現代化建設主線，舉辦「聚焦新質生產力」、「固本培元」、「預見2025」等大型策略會，搭建上市公司與機構投資者交流平台，服務實體經濟發展並首次在香港舉辦投資策略會，重點服務海外機構投資者。在企業客戶服務方面，公司堅持以客戶需求為導向，構建全業務鏈、全生命週期的投資銀行服務體系，堅守金融服務實體經濟初心，把功能性放在首要位置，著力打造產業投行、科技投行。截至2024年末，公司作為主辦券商持續督導掛牌公司共計44家，其中「專精特新」企業佔比達84.09%。同時，公司高度重視債券業務服務國家戰略，以金融力量助推高品質發展。報告期內，主承銷各品種科技創新債券110期，承銷金額344.79億元；主承銷各品種低碳轉型和綠色債券18期，承銷金額56.31億元；主承銷鄉村振興債券5期，承銷金額11.19億元。公司多措並舉加強執業品質管控，在證券業協會2024年度證券公司債券執業品質評價中獲得A類評價。此外，公司緊密圍繞國家產業政策、金融政策、區域發展政策指導方向，踐行「一個廣發」展業模式，主辦新質生產力並購論壇、廣東資本市場並購聯盟成立大會等多個大型並購主題活動，致力於構建並購業務生態圈，為客戶提供多層次、全方位的綜合服務，促進資產資本有序循環。報告期內，公司產業研究院持續打造產、學、研、投、融生態，賦能各業務板塊發展，為政府部門的政策制定與產業規劃提供研究支持，探索與重點科研高校建立產業孵化轉化合作機制，發揮「科技-金融-產業」的橋樑作用。深耕「五篇大文章」 積極履行社會責任作為20世紀80年代末至90年代初成立的第一批券商中為數不多的未經歷過因經營虧損而接受注資和重組的主要券商之一，廣發証券始終保持強烈的家國情懷，秉持「以價值創造成就金融報國之夢」的使命感，傳承以「知識圖強，求實奉獻」為核心的企業價值觀，發揚「博士軍團」的優秀文化基因，以知識為保障，以專業為基石，服務實體經濟量質雙升。報告期內，公司主動融入國家發展大局，深耕「五篇大文章」。公司在科技金融方面重點發力，股權投資30家科創企業，為42家科技企業股債融資1,470億元，設立6只科創產業投資基金，滿足各類科創主體投融資需求。持續構建綠色金融服務體系，發佈《綠色能源產業發展藍皮書》等11篇深度研究報告，支持綠色領域產業研究；承銷發行7單綠色ABS項目，融資147.59億元，為綠色產業提供多樣融資管道；自有資金投資綠色債券59.93億元，為綠色領域發展注入金融活水。加大養老金融業務佈局，累計發行養老目標基金產品24只，合計規模69億元，打造多層次的養老金融服務體系。持續探索數字金融應用與實踐，累計落地43個AI大模型應用，場景數量和業務覆蓋保持行業領先。同時，公司堅守「金融報國、金融為民」的理念，積極履行社會責任。報告期內，公司聚焦「鄉村振興、助學興教、金融賦能、醫療救助」等領域，公益支出達2,267.60萬元。發起設立的廣發公益基金會累計公益支出超過3億元。在ESG治理水平提升上，公司加強集團全面風險管理，嚴守合規經營底線，提高投資者保護和股東利益回報水平，綜合實現每股社會經濟貢獻值4.29元，連續多年被納入恒生可持續發展企業指數系列。未來，廣發証券將以新時代中國特色社會主義思想為指導，在服務國家戰略中求發展，在擁抱科技革命的大潮中求發展，在創新變革中求發展，奮力譜寫建設國際一流投行的嶄新篇章！ Copyright 2025 亞太商訊 via SeaPRwire.com.

Financial Highlights (Audited)(HKD Thousand)Year ended 31 December20242023ChangeRevenue271,372262,801+3%Gross Profit104,72090,666+16%Profit Attributable to Owners of the Company33,44021,338+57%Gross Profit Margin39%34%+5 p.p.Basic Earnings per Share (HK cents)2.371.62+0.75HK centsHONG KONG, Mar 29, 2025 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2024 (“the Year”).In 2024, due to the improvement of sales benefited from the gradual economic recovery and continuous innovation in product and consumption scenarios of the Group, the revenue of the Group increased by 3% year-on-year to HK$271 million. And due to other gains arising from emoluments of certain former directors waived of approximately HK$12.2 million, the Group’s profit attributable to owners of the Company increased by 57% year-on-year to HK$33.4 million. Earnings per share of the Company (the “Share”) was HK2.37 cents per Share. The Board recommends resumption of dividend distribution and a final dividend of HK 0.35 cents per share for the year 2024.Sales of white wine products grew well over the year and served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 41% and 56% for the year (2023: red and white wines: approximately 52% and 44%). The gross margin of red wine products and white wine products in 2024 were 37% and 41% respectively (2023: 32% and 38% respectively). The overall gross profit margin increased to 39% in 2024 (2023: 34%), mainly due to control in production costs and reduction in certain reimbursement of market expenses under sales arrangement during the year.The Group completed the development of the first phase of Tianxia Winery and its ancillary premises, located in the Pigeon Hill Wine Cultural Tourism Town in Qingtongxia City, Ningxia, in the third quarter of the year. The winery is situated nearby Eastern foothill of Helan mountain, Ningxia, which is one of the key quality grape producing regions in the PRC. It integrates pressing, fermentation, processing, testing and research and development as a whole, with an annual production and processing capacity of 5,000 tonnes. Pressing, fermentation, processing facilities had a pre-run in the third quarter of the year. The winery will become a new long-term and stable economic growth point of the Group and help the regional presence and layout of Dynasty wines, as well as aligning with the overall planning and industry planning for the development of China’s wine industry.During the year, the Group approved the set up of two joint venture companies, which have been established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine in Dongtai City, Jiangsu Province, the PRC and trading of sauce-flavour baijiu products nationwide respectively. For the yellow wine project, construction of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu will be kick-started by the joint venture company in the first half of 2025. The plan starts with special yellow wine – Dongtai Chenpi Wine with a goal to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry, and achieve a major strategic move towards high-quality development of the wine industry. For the sauce-flavour baijiu segment, Dynasty Group’s strategic involvement in this field is an attempt to break through the current wine category innovation. By integrating upstream and downstream related parties to jointly establish a new company, we construct a business model of benefit sharing, risk sharing, continuous cooperation and innovation mechanism. Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang ’, ’Song ’ and ‘Ming ’ are newly launched to the market, satisfying the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the enduring improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new high-end product, i.e.Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Jia Chen Year of Dragon, integrating the high quality wine with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. It launched a new product, Inherit Series “Passing on the Glory, Continuing the Brilliant Heritage”, at the 110th China Food & Drinks Fair in March 2024, as well as other new products launched in the year such as Long Yun Series, Cabernet Reserve, etc., to further improve its product matrix and provide consumers with diverse consumption choices. With leading and well-proven technologies it prides, the Group carried out comprehensive upgrade of its production techniques, packaging design, etc. With China chic on the rise, the new upgraded design is set to resonate with Chinese consumers who are proud of their culture, help strengthen awareness of the Dynasty brand and attract mainstream consumers fancying China-made products and China chic.In addition to enriching the product matrix, the Group has been accelerating the innovation of consumption scenarios and enhancing and strengthening the wine cultural experience. In June and July 2024, Dynasty Starry Wine Bars were officially opened in Tianjin, the base of Dynasty. Starry Wine Bar is a pop-up offline bar meticulously designed by Dynasty to innovate the product experience, meet the diversified needs of consumers, and create new consumption scenarios in the country. It is committed to making consumers feel the warmth of the brand and recognise the value of the brand, thereby attracting more consumers through innovation. During the year, the Group continued to develop the “Dynasty Tavern” through online channels, creating a series of product promotion articles on the WeChat official account of Dynasty Wines, and promoting Dynasty’s major mainstream products using new media formats. In addition, it integrated the night market environment to expand various wine drinking scenarios and promote Dynasty’s younger products.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional ecommerce platforms, such as JD.com , Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote , Kuai and TikTok during the year. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. During the year, the Group kept promoting the exclusive products series for e-commerce platforms through channels such as live streaming or broadcasting, in addition to mere presence on mainstream traditional e-commerce platforms which kept growing. Efforts have been made by the Group to consolidate the existing channels and improve their effectiveness as well as the profitability on its interest-based e-commerce coverage. Thus, the e-commerce sales consolidated with a certain decrease during the year, but a prominent improvement has been made with an overall profit achieved when compared with last year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2025, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines. The Group will further strengthen presence in Ningxia and Xinjiang to secure the supply of quality grapes and grape juice. Following the completion of Tianxia Winery (Phase I) in Ningxia, related new quality wines brewed from locally sourced premier grapes and grape juice will be launched, heeding different market and consumer demands. In addition to our commitment to core wine business in the PRC, the Group will further develop new alcoholic beverages segments such as sauce-flavour baijiu, yellow wine and special yellow wine - Chenpi wine, through the newly set up joint venture companies in 2025, so as to diversify the sources of revenue. In view of the continual resumption of economic growth and consumption in the PRC, the Board currently remains cautiously optimistic on the business in 2025. The Group will continue to proactively develop new marketing prospects through innovation in products categories and consumption scenarios, and cross-industry co-operations in order to boost sales volume, which is in line with the country’s effort to promote domestic consumption and release the consumption growth potential.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月29日 - (亞太商訊 via SeaPRwire.com) - 3月28日，同仁堂國藥發佈2024全年業績，未來同仁堂國藥是否會迎來行情？存在哪些投資機會？今天我們來聊聊這個話題。一、同仁堂國藥的「確定性之錨」資本真正關注的價值點是什麼？歸納起來，大體為賽道、基本面和長期價值，並找到投資標的「確定性之錨」。正如巴菲特有一句膾炙投資界的名言，「人生就像滾雪球，最重要之事是發現濕雪和長長的坡。」用滾雪球來比喻長期主義下的複利增長，帶來的巨大財富積累。濕雪比喻年收益率高，長坡比喻複利增值時間長。1.持續兌現業績成長，盈利增長能見度高，優質基本面不斷鞏固具體來看，同仁堂國藥便是一家符合「長坡濕雪」基本特徵的公司，具有穩健基本面、業績兌現能力強、護城河鞏固的中藥企業。從財報不難發現，同仁堂國藥憑藉優質的核心產品以及海外佈局加強了成長性、確定性。收入端看，2024年，同仁堂國藥實現收入1,611.6百萬港元，較2023年的1,524.9百萬港元，同比增長5.7%。2024年，香港地區市場收入為1069.7百萬港元，與2023年的915.3百萬港元，同比增長16.9%。從2013年上市至2024年，同仁堂國藥收入的年複合增長率為8.38%，淨利潤年複合增長率為7.27%。支出端來看，同仁堂國藥整體費用結構保持比較穩定狀態，成本端仍然控制良好。公司基本沒有有息負債，財務費用長年處於較低水平。2024年一般及行政開支占收入百分比為11.9%，與去年的11.7%大致持平。而2024年分銷及銷售開支佔比由去年的15.2%增長至本年的18.6%，主要是由於零售終端數目增加，加上公司加強及增辦重點產品及品牌的營銷推廣活動，令廣告及宣傳費用同比有大幅增加。銷售開支增長，釋放「搶市場」信號，也將反應到未來的營收增長。從盈利端來看，同仁堂國藥毛利率過去五年平均達到69%左右。這也得益於的安宮牛黃丸和靈芝這兩個拳頭產品為公司積累了大量的現金。值得注意的是，同仁堂國藥不斷研發新產品，這無疑是未來新的贏利點。高ROE（淨資產收益率）是衡量企業盈利能力的重要指標，也是資深投資者選股的重要指標。按照「奧馬哈先知」查理芒格的觀點：投資一家企業的長期回報率，大概就等於這家企業的淨資產收益率。同仁堂國藥在2019年及以前，ROE甚至超過20%。此外，公司經營活動現金流充裕。2024年公司現金和現金等價物為18.20億港元，負債比率2.9%，財務狀況穩健。整體來看，同仁堂國藥財務槓桿很低，利潤含金量很高，毛利和淨資產收益率也很出色，公司現金充裕且負債很少。整個財務面可以說是相當優秀的，這也是好的生意模式的體現。同仁堂國藥是類似於喜詩糖果的企業。雖然增長偏慢，但增長的持續性強、穩定性好、利潤率高、現金回報高而資本開支低，具有提升股息的潛力。筆者查了下，同仁堂國藥一直保持較高的派息率，2024年的派息率達58.6%，上市後累計分紅達30億港元。從分紅視角來看，同仁堂國藥穩定的利潤增長和持續健康的現金流狀況，為其提供了持續穩健的分紅基礎，這也意味着投資者能夠獲得較好的收益回報，增強了投資的安全墊。對於求穩的投資者來說，進，可以博股價，退，可以賺股息，攻守平衡，慢慢變富，其實也挺香的。2.受益政策支持和中醫藥文化認可度逐步提高，中醫藥行業有望迎來加速成長和市場規模擴張的良機，行業增長潛能不斷兌現隨着我國步入老齡化社會，中醫藥文化認同不斷加深，上到治未病、慢性病管理、輔助康復及健康養老，下到年輕人亞健康養生，中藥與每個人的生活息息相關，對傳統中醫藥的認可度和使用率也在不斷提高。根據相關數據顯示，2023年我國中藥市場整體規模有望突破萬億元。與此同時，全球健康意識和對中藥文化認可度的提升，中醫藥在全球市場的潛力日益凸顯，境外零售規模將繼續擴大。而在政策端，近幾年政府積極扶持中醫藥行業的發展，出台了許多促進中醫藥發展的相關政策，為中藥行業帶來政策紅利和新增需求。伴隨政策面持續推動、市場需求加速釋放，整個行業業績增長潛能還將不斷兌現。3、核心產品安宮牛黃丸具有稀缺屬性，構築堅固品牌護城河中國有兩類「黃金」：一類埋在地下，一類藏在藥櫃裏。安宮牛黃丸這類品牌中藥的定價邏輯，本質是時間、技藝與稀缺性的三重複利。北京同仁堂擁有356年的歷史，而同仁堂安宮牛黃丸有文字記載的傳承至今150多年。在百餘年中，同仁堂將自身的製藥工藝和清宮御藥房製藥標準、傳統中醫藥文化和中華文化有機結合，形成了安宮牛黃丸傳統製作技藝，並在2014年入選第四批國家級非物質文化遺產代表性項目名錄。同仁堂國藥是北京同仁堂集團海外市場平台，主打（雙天然）安宮牛黃丸和破壁靈芝孢子粉膠囊。其中，同仁堂國藥在香港製造的安宮牛黃丸，在其目標消費者心中有着無可比擬的地位，擁有很強的提價權，備受消費者追捧，在香港地區市場份額排名前列。2006年同仁堂國藥在中國香港大埔工業區的生產基地建成，成為同仁堂首個在北京區域外的中藥及保健品研發生產基地，也是中國香港少數獲得GMP認證的中藥生產企業。安宮牛黃丸生產工藝質量與藥品治療效果密切相關，其非遺加工工藝和原材料形成了有利的技術壁壘。在行業景氣度持續升溫背景下，同仁堂國藥的核心產品極具高競爭壁壘和品牌護城河，成長天花板正不斷築高。二、同仁堂國藥中長期成長潛力分析作為投資者，在深入理解同仁堂國藥核心價值亮點之後，自然會將視角轉向公司未來的發展潛力和成長空間。1、銀髮經濟催化需求，帶動內地市場增長最新人口結構數據顯示，2024年底中國內地60歲及以上人口佔比已達21.1%，其中65歲及以上人口佔比15.4%。這一數據表明，中國內地已邁入中度老齡化社會。據國家衛健委預測，我國60歲及以上的老年人在2035年將達到4億，佔全國人口總數的近30%，進入重度老齡化階段。在老年健康需求持續增長的大環境下，背後蘊藏的是一個巨大的銀髮經濟藍海市場。中醫藥作為我國獨特的衛生資源，憑藉其在治療慢病領域的獨特優勢，有望在「銀髮經濟」持續升溫的背景下率先跑出加速度。同仁堂國藥出品破壁靈芝孢子粉膠囊，經由同仁堂集團成員在中國內地代理經銷，用於年老體虛、體弱多病等各類免疫功能低下人士增強體質改善症狀，改善睡眠質素。在破壁靈芝孢子粉膠囊市場需求帶動下，2024年公司在中國內地市場收入為139.4百萬港元，同比增長7.8%。2、安宮牛黃丸粉採購建議上限有所提升，王牌產品量價齊升趨勢不改安宮牛黃丸享有「救急驟於即時，挽垂危於頃刻」的美譽。除了傳統心腦血管領域，安宮牛黃丸應用不斷擴展。隨着國內外大量基礎研究和臨床實驗開展，進一步闡明安宮牛黃丸作用機制和臨床療效，安宮牛黃丸在感染性疾病、老年病以及日常保健等潛在應用領域需求有望得到逐步釋放。根據公司公告，同仁堂國藥與同仁堂股份訂立自2025年1月1日至2027年6月30日的續訂安宮牛黃丸粉採購框架協議，2025年、2026年及2027年上半年續訂安宮牛黃丸粉採購框架協議的建議新上限6500萬、6900萬、3600萬，較此前年份均有一定增長，可以看出國藥管理層對此的樂觀。天然牛黃作為安宮牛黃丸的主要材料之一，價格近年來大幅上漲，天然牛黃價格超過黃金。儘管牛黃市場的價格走勢一路上漲，源自中醫市場的剛性需求增大，作為名貴藥材的牛黃越來越火爆。基於安宮牛黃丸在治療疾病方面具有一定的效果，市場認可度較高，其他產品的替代性較小，上游漲價絲毫不影響整體市場強勁需求。在原材料上漲和下游需求的穩中有增背景下，從上市至今，同仁堂國藥安宮牛黃丸受惠於市場整體加價進行數次上調。不過，同仁堂國藥安宮牛黃丸的提價幅度和次數要溫和的多，這也為同仁堂國藥未來業績的釋放留下了一定空間。3、持續深化出海佈局，構建多元渠道，不斷拓展成長邊界數據顯示，海外華僑華人超6000萬。截至2024年末，同仁堂業務網絡覆蓋亞洲、大洋洲、北美洲、歐洲主要國家及地區，開辦各種零售終端(藥店、中醫診所和中醫概念的養生中心)超過160家。1）持續推進重點產品在海外國家的註冊上市以前，中成藥大多只能作為膳食補充劑進入國際市場；近年來，以天然藥物和傳統藥註冊上市的中成藥越來越多。在東南亞、澳洲等具有中醫基礎的區域，同仁堂國藥積極推動產品註冊。2025年2月，同仁堂集團董事長戴小鋒率隊拜訪柬埔寨王國衛生部,與柬方洽商安宮牛黃丸在柬註冊等事宜。2024年，同仁堂國藥進一步跟新西蘭鹿業局合作，開發以新西蘭鹿茸和鹿副產品為主要成分的新型保健食品。此外，同仁堂國藥利用新西蘭地區的優質資源優勢，結合同仁堂的中醫藥概念，在新西蘭設置鹿產品廠房，拓展健康概念新領域。2）與大學院校合作構建產學研用一體化平台，開啟中醫藥現代化之路中西方文化理念的差異導致歐美公眾不理解中醫藥。由於文化背景和理論體系不同，中醫藥的科學內涵尚未被國際社會特別是歐美社會廣泛接受，中藥海外註冊面臨政策壁壘。如何用現代科學語言闡述清楚中醫藥理論，是當前業界迫切需要解決的問題。同仁堂國藥通過與大學院校合作不同科研項目，構建產學研用一體化平台。2024年，同仁堂國藥與澳門科技大學簽署合作意向書，開展科研合作研究，促進科研成果轉化、開展同仁堂中成藥產品在澳門的註冊等。在此基礎上，同仁堂國藥與澳門科技大學藥學院簽署了《芪藥丸對改善高脂飲食加STZ模型誘導的糖尿病腎病藥效驗證及機制研究》合作協議，並與澳門科技大學藥學院合作計劃「經典名方黃芪桂枝五物湯、桃紅四物湯處方藥理學考證及製劑優化研究」，為經典名方的傳承與發展提供有力的科技支撐。這些積極、明確的研究成果，既對公司重點品種未來的發展提供理論研究依據，也為重點品種打開海外市場積累了口碑、認知度以及技術保障。4、強化產品生產研發，發展新質生產力，向價值鏈高端攀升在政策鼓勵以及中藥「治未病」、「純天然」特有優勢下，中藥創新再度加速，新藥上市節奏加快，中藥行業」新質生產力+消費「雙屬性愈加明顯。靈芝孢子粉是同仁堂國藥的獨家品種，可以說是整個同仁堂集團在新品創新力方面，近十年最為成功的大單品。2024年，同仁堂國藥相繼推出同仁堂仙齡、保齡中式抗衰老NMN系列產品、靈芝薑黃複方活血安神膠囊、桂枝茯苓丸、活絡油等新產品，擴大自有產品矩陣。「當歸補血顆粒【同仁堂】」及「金釵石斛散【同仁堂】」分別在2024年及2025年通過香港中醫藥管理委員會審批獲得中成藥註冊證，進一步豐富了其品種資源。2024年4月，公司下屬單位北京同仁堂(海南)控股公司(以下簡稱「海南控股」)申報的「一種祛斑美白產品及其製備方法、用途」發明專利獲得國家知識產權局發明專利正式授權。該專利配方已應用於同仁堂國藥首款中式抗衰老產品保齡清靚版中，產品已在中國香港地區上市。2025年2月，海南控股申報的「一種抗衰老產品的製備方法及其用途」發明專利(專利號:ZL 2023 1 1235947.6)成功獲得國家知識產權局發明專利正式授權。這是繼2024年4月取得發明專利後，在不到一年內取得的又一重要成果。5、加強線上渠道拓展，提升了未來成長空間 近年來，線上經濟加速發展，直播電商等新渠道、新模式成為風口。同仁堂國藥積極探索線上新興渠道及模式，進一步提升了未來成長空間。此前，同仁堂國藥已經自建網絡商城，方便用戶線上購買。面對渠道變革的超級增量風口，公司已經取得明顯的先發優勢。2024年，同仁堂國藥繼續加強在電商渠道的佈局，分別與京東健康、阿里健康及有贊等合作開展電商跨境銷售業務，重點打造了破壁靈芝孢子粉膠囊及靈芝薑黃複方活血安神膠囊等產品的在線推廣。在香港零售業仍然面臨挑戰，到訪旅客和本地市民消費模式明顯轉變下，同仁堂國藥正利用線上渠道，接入中國內地14億人口大市場。三、港股醫藥板塊價值重估風起，同仁堂國藥估值幾何？過去一年，港股市場的定價體系迎來了新的扭轉契機。過去長期被壓制的醫藥板塊，在南下資金持續加碼下具備重估的契機。當估值水位與戰略縱深形成共振，同仁堂國藥這類兼具安全邊際與成長動能的企業，往往就是資金暗流中最值得打撈的標的。1. 估值處於歷史低位，公司內在價值嚴重低估從最近十年的估值表現來看，同仁堂國藥雖然持續業績增速，然而對應估值卻處於歷史低位。這背後很大一部分原因在於港股市場投資人尤其是外資長期以來對中醫藥的不了解。中藥品牌歷史源遠流長，品牌價值高，存續久期長，應當給予比普通消費品更高的估值。因此，同仁堂國藥仍然有一定的潛力空間。數據來源：iFIND,2025/03/28,同仁堂國藥近十年估值若以PE方法對公司進行估值分析，考慮到王牌產品安宮牛黃丸量價齊升趨勢有望持續，同時產品屬性與片仔癀接近，兼具高壁壘、稀缺性和高成長性，我們選取片仔癀、東阿阿膠、雲南白藥等品牌中藥作為可比公司，PE估值區間為27.6X。同仁堂國藥當前對應的市值至少為138億港幣，對應每股股價為16.56元港幣，距當前股價還有89%的空間。數據來源：iFIND,2025/03/28,可比公司估值2)有望迎來估值和業績共振的」戴維斯雙擊」從長期來看，港股整體估值並未過高，仍然是全球估值窪地，且不少標的具有稀缺性，這意味着其未來的估值修復空間可能更為可觀。同仁堂國藥當前股價處於歷史性低位，成長的天花板正不斷築高，作為行業內長期穩健型選手，中長期成長空間值得期待，有望迎來估值和業績共振的」戴維斯雙擊」。 Copyright 2025 亞太商訊 via SeaPRwire.com.

財務摘要 (經審核)（港幣千元）截至十二月三十一日止年度2024年2023年變動收入271,372262,801+3%毛利104,72090,666+16%本公司所有者應佔溢利33,44021,338+57%毛利率39%34%+5個百分點每股基本盈利 (港仙)2.371.62+0.75港仙香港, 2025年3月29日 - (亞太商訊 via SeaPRwire.com) - 中國優質葡萄酒生產商王朝酒業集團有限公司(「王朝」或「集團」)(股份代號：00828)今日公佈截至2024年12月31日止（「年內」）經審核之全年業績。2024年，受惠於全國經濟逐步復甦及集團不斷創新產品及消費模式令銷售改善，集團收入較去年同比增加3%至2.71億港元，另外由於年內豁免若干前董事酬金產生的其他收益約 12.2百萬港元，本公司所有者應佔溢利較去年同比增加57%至33.4百萬港元，每股基本盈利為每股2.37港仙。董事會建議恢復派息，2024年度派發末期股息每股 0.35港仙。集團白葡萄酒產品的銷售於年內錄得良好增長，成為集團主要的收益貢獻來源。紅葡萄酒及白葡萄酒產品的銷售分別佔集團於年內收入的約41%及56%（2023年：紅葡萄酒及白葡萄酒：約52%及44%）。於2024年，紅葡萄酒產品及白葡萄酒產品的毛利率分別為37%及41%（2023年：分別為32%及38%）。整體毛利率增加至39%（2023年：34%），主要由於年內控制生產成本及銷售安排項下的市場推廣費用的報銷減少所致。集團於2024年第3季度完成位於寧夏青銅峽市鴿子山葡萄酒文化旅遊小鎮的天夏酒莊（一期）及其附屬廠房的開發項目。該酒莊毗鄰中國優質葡萄主產區之一的寧夏賀蘭山東麓。其集壓搾、發酵、處理、化驗及研發於一體，年生產及加工能力為5,000噸。壓搾、發酵、加工設備已於2024年第3季度投產試運行。該酒莊將成為集團新的長期穩定經濟增長點，有助於王朝葡萄酒的區域佈局，符合中國葡萄酒行業發展的整體規劃及行業規劃。年內，王朝批准新設立兩間合資公司，並於2025年2月成立，分別於中國江蘇省東台市生產及銷售黃酒及陳皮酒，以及於全國範圍內買賣醬香型白酒產品。對於黃酒項目，合資公司將於2025年上半年在江蘇啟動建設一座儲罐容量為3,000噸黃酒及特種黃酒－陳皮酒的生產廠房。計劃從特種黃酒－東台陳皮酒開始。此舉目標旨在有效擴展產品品類，把握中國黃酒行業的發展機遇，實現酒業高質量發展的重大戰略舉措。對於醬香型白酒領域，王朝集團策略性涉足此領域，乃對當前葡萄酒品類創新的突破嘗試。通過整合上下游相關方共同設立新公司，構建利益共享、風險共擔、持續合作及創新機制的商業模式。王朝醬香型白酒產品，即「漢」、「唐」、「宋」、「明」，全新推向市場，滿足不同消費習慣的客戶群體的需求，並為集團業務作出貢獻。未來，醬香型白酒產業的持續發展及擴張及客戶群體水平的持久提升，必將及有效推動王朝葡萄酒及相關產品銷售規模的增長，從而提升行業影響力及品牌知名度。集團積極求新，聚焦「5+4+N產品戰略」，其中「N」代表集團推出N項需求定制，不斷開拓創新產品，以滿足中國不同類型消費群體的多元化需求。年內，集團推出中高端新品－王朝甲辰龍年生肖紀念乾紅葡萄酒，將高端品質酒品與中國生肖文化相融合，引領「國潮風」。此外，基於其現有的優質產品，集團繼續推出新產品並推進產品升級。集團於2024年3月在第110 屆全國糖酒商品交易會上推出新品傳承系列「續寫輝煌，傳承經典」，以及年內推出龍運系列、珍藏解百納等其他新品，以進一步完善其產品矩陣，為消費者提供多元的消費選擇。集團憑藉自家領先及傳承的技術，對產品的工藝、包裝設計等進行了全面升級。隨著國潮的崛起，全新升級的設計更易觸發中國消費者內心文化自信的共鳴，進一步加強王朝品牌的認知度，並吸引追求國貨及國潮的主流消費群體。除了豐富產品矩陣外，集團正在加速創新消費場景，提升及強化葡萄酒文化體驗。於2024年6月及7月，王朝星空酒吧於王朝基地天津正式開業。星空酒吧是王朝精心設計的線下快閃酒吧，旨在創新產品體驗形式，滿足多元消費需求，打造國民消費新場景。其致力於使消費者感受到品牌溫暖及認同品牌價值，從而用創新圈粉更多的消費者。於年內，集團通過線上渠道，持續打造「王朝小酒館」，在王朝酒業微信公眾號打造系列產品推介稿件，利用新媒體形式，推廣王朝各大主流產品。結合夜市的環境，拓展葡萄酒多種飲用場景，推廣王朝年輕化產品。電商銷售方面， 集團的電商團隊於傳統電商平台全面運營在線商店銷售產品，例如京東商城、天貓商城及拼多多，以及通過興趣電商平台（包括小紅書app、快手app 及抖音app）全面創新品牌、品類、業務體系、流程和模式。集團繼續為改善網上銷售渠道及時投入資源，優化在線商店界面，以把握中國客戶消費行為的變化。年內，集團積極通過直播或廣播等渠道推廣電商平台上的獨家產品系列，除主流傳統電商平台維持增長外，集團竭力整合現有渠道並改進其效益及以及利益型電商覆蓋的盈利能力。因此，經整合的電子商務銷售額於年內有若干的下降，但整體實現了盈利較去年明顯改善。集團相信線上平台不僅是集團與消費者之間的企業對客戶交易平台，亦是品牌新增的市場推廣及宣傳渠道，此更可提升集團的整體業務潛力。王朝主席萬守朋先生總結︰「展望2025年，集團將繼續以市場及消費者需求為導向，重塑消費埸景，提升產品質量。同時，集團將繼續創新市場營銷策略，激發品牌活力，進一步擴大王朝產品的市場佔有率，加強王朝品牌作為國產葡萄酒代表的形象。集團將進一步加強在寧夏及新疆的佈局，以獲取優質葡萄及葡萄汁供應。寧夏天夏酒莊（一期）落成後，將推出以當地採購的優質葡萄及葡萄汁釀製的相關優質新品葡萄酒，以滿足不同市場及消費者需求。除致力於中國核心葡萄酒業務外，集團亦將通過2025年新設立的合資公司，進一步拓展至新的酒類飲料領域，如醬香型白酒、黃酒及特種黃酒-陳皮酒，以實現收入來源的多元化。鑒於中國經濟增長及消費持續恢復，董事會目前對2025年的業務保持審慎樂觀。集團將繼續通過產品品類及消費場景的創新，以及跨行業合作，積極開拓新的營銷前景，以提升銷量，藉此支持國家擴大內需及釋放消費增長潛力的工作。」關於王朝酒業集團有限公司王朝酒業集團有限公司於2005年1月26日在香港聯合交易所有限公司主板上市，股份代號00828。成立於1980年，王朝為中國優質葡萄酒生產商，主要生產及銷售「王朝」商標的葡萄酒產品，是中國第一家中外合資的釀酒企業，主要股東包括天津食品集團有限公司及法國葡萄酒巨頭人頭馬集團。集團產銷葡萄酒産品系列超過100種，及引入進口葡萄酒產品，為國內各消費層提供高質素及物超所值的葡萄酒。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 飛魚科技國際有限公司（「飛魚科技」或「公司」或「集團」，股份代號：1022.HK）董事會欣然宣佈本集團截至2024年12月31日止年度的綜合年度業績。截止2024年12月31日止年度，飛魚科技收益總額約人民幣276.7百萬元，同比增長22.4%。其中，遊戲營運收益約為人民幣238.8百萬元，較2023年度約人民幣174.7百萬元增加約36.7%，該增長主要由於在2024年8月1日推出廣受用戶歡迎的「一步兩步」。2024年，中國線上遊戲行業複甦趨勢顯著，而其中HTML5遊戲表現尤為突出，收益同比增長近100%至人民幣398億元。飛魚科技緊抓機遇，於2024年成功推出以HTML5遊戲為主的三款新遊戲，其中「一步兩步」憑藉獨特玩法與高質量體驗，贏得玩家高度認可，並於2025年1月在微信小遊戲暢銷榜攀升至第八位。該遊戲在營运收益與廣告收益方面貢獻顯著，已成為驅動公司收益增長的核心動力。未來，飛魚科技將繼續於HTML5、手機應用程式及主機等多個平台開發新遊戲，並且將充分發揮自身優勢，持續投資「一步兩步」，進一步挖掘其市場潛力。同時，公司計劃於2025年上線主機遊戲「霓虹深淵2」，拓展多平台佈局，以滿足不同玩家群體的需求。值得關注的是，在積極投資推出新遊戲的同時，公司長期運營的經典遊戲「神仙道」、「三國之刃」及「保衛蘿蔔」系列也仍持續提供穩定現金流。其中，「保衛蘿蔔4」廣告收益同比增長22.2%，用戶黏性穩固且持續吸引廣告主，體現了公司培育及維持既有知識產權的能力，這也彰顯了公司的知識產權於激烈的市場競爭中仍保持強勁的盈利能力。此外，公司還積極擴展知識產權邊界，推出以「蘿蔔阿波」為原型的收藏模型，2024年，該系列新增6個產品系列，部分限量模型發售5分鐘即售罄。為進一步強化知識產權與粉絲之間的情感連結，提升知識產權商業價值，飛魚科技還通過展覽、快閃活動及文化沙龍等各種線下渠道，提高相關知識產權的實際曝光率。這種線下活動一方面可以深化與現有粉絲的互動，另一方面也可以吸引更多新客戶，在一定程度上展現了公司於在線遊戲之外的創新及價值創造能力，有助於進一步鞏固公司的品牌影響力和市場佔有率。展望未來，飛魚科技表示，儘管行業或將面臨競爭激烈、客戶獲取成本上漲及消費者信心減弱等挑戰，但公司有信心憑藉在創造具吸引力且富文化底蘊的遊戲體驗方面的專業知識把握機遇。此外，公司還計劃挖掘海外市場機遇，將旗下遊戲推向更廣泛的全球受眾，豐富收益來源，為玩家與股東提供持續價值。關於飛魚科技國際有限公司飛魚科技是國內領先互聯網遊戲開發和運營商，本著"用簡單創造精彩"的企業理念，致力於互動娛樂產品的研發與運營。2014年12月，飛魚科技成功登陸香港聯交所上市（01022.HK），為廈門地區首家在香港上市的遊戲公司。飛魚科技在全國進行戰略化佈局，分支機構遍佈北京、深圳等國內主要城市；集團旗下擁有數款精品網路遊戲產品，如《神仙道》、《保衛蘿蔔》系列、《三國之刃》、《超級幻影貓》系列等，並在多個細分領域開展專業化佈局，陸續推出了《英雄就是我》、《初體計劃》、《你胖你先吃》等多款精品獨立遊戲及輕度休閒遊戲。憑藉優質的產品、服務品質、受歡迎程度獲得多項行業重要獎項及玩家認可，累計遊戲用戶數超過十億，遍及中國大陸及海外地區。如欲瞭解更多關於飛魚科技，請瀏覽https://www.feiyu.com/。如有垂詢，請聯絡慧悅公共關係顧問集團有限公司：Anne Lin / Ken Wu / Jane Zhuang電話：(86) 13556417482 / (86) 15607493246 / (86)13537575478電郵：anne.lin@intelligentjoy.com / ken.wu@intelligentjoy.com / jane.zhuang@intelligentjoy.com Copyright 2025 亞太商訊 via SeaPRwire.com.

深圳, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 由深圳市殘聯和龍華區人民政府指導，區殘工委主辦、區殘聯承辦的"孤獨星球-星光跑"公益活動將於3月30日上午在深圳龍華人才綠道群賢廣場正式開跑。本次活動旨在提升社會對自閉症群體的認知，推動社會各界共同為他們構建更加友好的成長環境。作為本次活動的主要協辦單位，深圳海納特教集團正積極籌備，號召自閉症兒童及家長、特教從業者和社會各界愛心人士踴躍參與。孤獨症，又稱自閉症，是一種廣泛性發育障礙，主要表現為社交障礙、語言溝通困難和刻板行為模式。世界衛生組織（WHO）資料顯示，全球每100名兒童中就有1名被診斷為孤獨症。為提高公眾對這一群體的關注度，聯合國自2008年起將每年的4月2日設立為"世界自閉症關注日"。今年的孤獨星球-星光跑，正是為了在世界自閉症關注日前夕，通過運動和公益行動，讓更多人瞭解並接納自閉症群體。海納特教集團創始人郭潔波攜手同行"孤獨星球-星光跑"，用愛點亮星光本次星光跑活動，社會各界愛心人士和企業積極回應，踴躍報名參與並提供支持。活動將在3月30日早上7:30進行簽到和物資領取，並於8:30正式開跑。參與者將通過奔跑與陪伴，讓自閉症兒童及其家庭感受到社會的溫暖與關懷。"我們希望不僅僅是為孤獨症兒童提供康復和教育服務，更要讓社會認識到，他們的成長和發展需要社會各界共同努力。"郭潔波先生補充道，"同時，我們也希望吸引更多投資者關注特殊兒童教育產業，這不僅具有重要的社會價值，也蘊藏著可持續發展的經濟潛力。"未來，海納特教集團將持續深化在孤獨症康復教育領域的探索，為更多特殊兒童及其家庭帶去希望與改變。關於中國自閉症兒童康復事業的可持續發展近年來，中國自閉症兒童康復和教育行業逐步發展，社會關注度不斷提升。然而，行業仍面臨專業人才短缺、服務資源分佈不均、長期資金支持不足等挑戰。根據《中國自閉症教育康復行業發展狀況報告》，我國孤獨症群體已超過1000萬人，其中兒童超過200萬。海納特教集團創始人郭潔波先生表示："特殊兒童教育不僅是一項公益事業，更是具備長期可持續發展的社會產業。隨著社會認知的提升和政府政策的支持，行業正在從單一的康復培訓模式向'康復+教育+就業'的多元化方向發展，為投資者提供了可觀的經濟回報。"他進一步指出："當前，社會資本的進入將加速行業的標準化和規模化，提升服務品質，同時推動技術創新，如智慧輔助康復設備、AI特教平臺等，使更多孤獨症兒童獲得更高效的成長支持。這不僅有助於解決社會問題，也能帶來穩定的長期收益。"未來，隨著政府、社會組織及市場資本的共同推動，中國自閉症康復與教育行業將迎來更廣闊的發展前景，實現經濟效益與社會效益的雙贏。構建自閉症兒童全生涯支持體系海納特教集團創始人郭潔波先生表示："孤獨症兒童被稱為'星星的孩子'，他們的成長離不開社會的支持。海納希望通過此次星光跑活動，讓社會各界更加關注這一特殊群體，促進自閉症人士的社會融合。"為了幫助孤獨症群體實現更好的發展，海納於2019年創辦了"海納星智夢工廠"，整合特教康復、職業培訓與就業支持，探索"康復教育+職前培訓+就業支持"的發展模式。在龍華區民政局的支持下，海納還註冊成立了深圳市龍華區海納兒童康復中心，為孤獨症兒童提供從學齡期到職前技能培訓、再到就業支援的全鏈條服務，助力他們更好地融入社會。關於海納特教集團海納特教集團成立於2009年，致力於為心智障礙者提供涵蓋早期干預、融合教育、職業培訓、支持性就業等在內的全生涯服務。截至目前，海納已為5000多名心智障礙人士提供支援，在深圳乃至整個大灣區享有良好聲譽。自2009年成立以來，海納不斷拓展服務體系，包括發育評估、早期康復、融合教育、職業技能培訓、支持性就業等，幫助孤獨症群體更好地融入社會，提升生活品質。瞭解更多，請關注http://hainatejiao.com/媒體聯絡品牌：深圳海納特教集團聯繫：媒體團隊電話：(+86)18025411773網站：http://hainatejiao.com/ Copyright 2025 亞太商訊 via SeaPRwire.com.

- 華堂寧(R)被納入國家醫保藥品目錄後的首個完整年度，銷量較2023年增加740%- 銷售收入較2023年增加234%，現金儲備超10億，充分支持未來研發和商業化活動- 第二代每天一次口服GKA在美國的I期臨床研究成功完成，多格列艾汀-二甲雙胍固定複方製劑順利推進，產品管線佈局逐漸豐富- 人類基因孟德爾隨機化研究提供科學證據，支援葡萄糖激酶啟動在糖尿病併發症和新適應症的開發- 多格列艾汀生產能力繼續擴大，滿足不斷增長的市場需求- 建立華領醫藥藥品市場銷售團隊，2025年前兩月銷售額顯著增長，開啟創新藥商業化新模式香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2024年12月31日止，經審核的全年業績（「報告期」），以及公司2024年業務進展和未來業務展望。華領醫藥在核心產品葡萄糖激酶啟動劑（GKA）多格列艾汀片（商品名：華堂寧(R)）的商業化，以及公司研發創新、產能優化等方面均取得了重要進展，為公司的長期可持續發展奠定了堅實基礎。華領醫藥創始人、首席執行官陳力博士表示：「2024年，華堂寧(R)的市場表現令人振奮，進入國家醫保目錄極大提高了產品的可及性和可負擔性，使得更多糖尿病患者能夠受益于這一創新藥物。2025年，華領醫藥建立了藥品市場銷售團隊，華堂寧(R)在年初展現出了良好的增長勢頭，隨著市場的進一步拓展和患者認知度的提升，我們對華堂寧(R)的市場增長充滿信心。未來公司將在全球範圍內繼續探索華堂寧(R)在糖尿病個性化治療以及糖尿病併發症等領域的用藥潛力，並且結合大資料和人工智慧技術,在免疫穩態和神經穩態方面，拓展我們的疾病治療領域。相信在華領醫藥及其藥品研發、生產、經銷商運營等產業鏈夥伴的密切合作下，我們能讓更多患者用上中國藥、受益於中國藥，加快推進『中華引領醫藥創新，造福人類健康進展』的公司願景。」臨床研究和公司運營進展摘要- 收入顯著增長，華堂寧(R)市場表現強勁，用藥回饋積極- 2024年是公司核心產品華堂寧(R)進入國家醫保藥品目錄後的首個完整銷售年度。公司銷售收入達到人民幣2.559億元，較2023年增加234%，華堂寧(R)的銷售覆蓋了約2700家醫院。截至 2024 年12月31日，華領醫藥現金結餘達人民幣11.398億元，以支持公司的全面商業化、業務發展和研發活動。- 自2022年第四季度華堂寧(R)上市以來，華領醫藥藥物警戒團隊始終高度關注對多格列艾汀藥物安全性的監測。近期，公司被國家藥品不良反應監測中心評為受表揚企業。截至2024年12月31日，華領醫藥已經監測了約15萬名開具華堂寧處方的患者，結果顯示安全性良好，患者耐受性佳。- 自2025年1月1日起，華領醫藥從原市場行銷合作夥伴拜耳醫藥保健有限公司（「拜耳」）手中全面接管華堂寧(R)在中國的商業化工作。公司已聘請資深銷售人士陸宇先生負責銷售和市場工作，他在中國的糖尿病藥物商業化方面具有超過20年的經驗。- 截至2025年2月28日止，華領醫藥在2025年前兩月共售出約59.2萬盒華堂寧(R)，淨銷售額約為人民幣7320萬元；相比2024年同期的20.2萬盒和2450萬元，淨銷售淨額增長顯著，在每盒價格維持不變的情況下，銷售額增長199%。這也證明華領醫藥已經順利接管華堂寧(R)在中國的商業化工作，且煥發出新的發展動力。- 與拜耳終止獨家推廣服務協定後，未攤銷的合同負債付款約12.435億元人民幣將，將在2025年確認為公司收益。雙方已在所簽立的函件中確認，概無任何因有關終止而引致的未決事項，雙方亦無因該分立而對彼此負有任何義務或責任。- 研發創新穩步推進，持續豐富產品管線佈局- 華領醫藥計劃將以葡萄糖激酶為靶點、以血糖穩態為核心的療法拓展至國際市場，特別是美國市場。2024年，公司在推進該項工作中取得了重大進展。公司成功完成並公佈了第二代GKA（HM-002-1005）在美國的單劑量遞增（SAD）研究結果，驗證了每日一次口服療法用於肥胖2型糖尿病患者的可行性。公司目前正在開發臨床劑型，以推進HM-002-1005的臨床機制驗證研究。- 華領醫藥在固定複方製劑的開發上也取得了重要進展，公司正在推進多格列艾汀-二甲雙胍固定複方製劑候選產品的商業化劑型開發，預計在2025年完成工藝驗證。- 根據從接受多格列艾汀治療的患者研究中收集的人類基因資料，應用孟德爾隨機化研究方法，預測多格列艾汀可能對糖尿病相關重大併發症產生獲益，如降低心力衰竭、冠狀動脈疾病、記憶力減退和血脂異常等的風險。此外，一項獨立的孟德爾隨機化研究提供了遺傳學證據，支援葡萄糖激酶的啟動對降低虛弱風險存在因果效應。這些研究結果表明，葡萄糖激酶啟動劑可能有助於控制糖尿病患者的體弱和肌肉疏鬆症。公司將繼續開展研發工作，以探索新的臨床適應症。- 通過在中國香港進行的 SENSITIZE 3臨床研究，華領醫藥正在推進多格列艾汀在糖尿病前期、2型糖尿病早期治療和預防方面的潛力。區別於已經獲批的75mg華堂寧(R)劑型，公司正在研究25mg和50mg新劑型，以探索上述新的潛在適應症。公司也在支持一項由研究者發起的研究，以探索多格列艾汀對患有葡萄糖激酶失活的基因突變（MODY-2）患者的治療效果。糖尿病領域知名專家陳重娥（Juliana Chan）教授和紀立農教授的進人研究均表明，多格列艾汀可改善MODY-2患者的β細胞功能和血糖控制。- 華領醫藥正在通過收集現實世界證據和動物模型的概念驗證研究，推進多格列艾汀與GLP-1RA、DPP-4抑制劑及SGLT-2抑制劑的聯合用藥研究。多格列艾汀與上述藥物的協同增效作用有望將其適應症拓展至代謝紊亂相關的其它疾病，如肥胖及代謝性相關的脂肪肝病。- 華領醫藥將繼續糖尿病預防、長壽機會以及記憶力衰退預防方面的研究，以期獲得延長人類健康壽命並實現長壽的全新方案。- 產能投資繼續擴大，多格列艾汀計劃推廣新市場- 華領醫藥繼續擴大產能的投資，以滿足2026年和2027年的預期市場需求。- 華領醫藥正在準備多格列艾汀在中國澳門和中國香港市場的商業化的註冊申請材料，公司計劃在 2025 年提交這兩項申請。- 華領醫藥繼續在全球範圍內加強智慧財產權保護。截至2024年12月31日，公司在全球範圍內擁有超過 200 項涵蓋專有技術的授權專利。業務展望- 在中國及全球口服抗糖尿病藥物市場，多格列艾汀和第二代GKA存在巨大市場機遇。- 華領醫藥將通過樞紐及輻射式發展模式來強化自身的商業化能力，重點打造華領醫藥內部銷售和醫學行銷團隊作為強大的樞紐，以推動2025年的業務增長。公司將建立與醫療界的緊密聯繫，更有效地在中國及周邊地區推廣華堂寧(R)。- 華領醫藥將繼續投資數位技術平台，以實現跨職能協同效應，並利用人工智慧技術提升品牌機遇。- 華領醫藥正在推進多格列艾汀在香港和澳門地區的註冊工作，並積極尋求與東南亞及「一帶一路」沿線國家建立合作關係。此外，基於在美國進行的SAD研究的初步成功，公司將繼續在西方肥胖人口密集地區開展第二代GKA的業務拓展工作。財務摘要截至2024年12月31日止，- 公司銀行結餘及現金約11.398億元。- 銷售收入約為人民幣2.559億元，較2023年全年增加約234%；共銷售約210.5萬盒華堂寧(R)，較2023年全年增加約740%。- 其他收入約為1.168億元，其中拜耳里程碑收益攤銷約9570萬元。- 年度總開支約4.936億元，其中研發開支約2.151億元。- 稅前虧損約 2.501 億元人民幣，主要原因是銷售費用和研發費用的增加。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧(R)（多格列艾汀片）以葡萄糖感測器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關資訊的，特別是標識或要求，應遵循中國監管機構批准的相關檔。另外，相關資訊不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Mar 25, 2025 - (ACN Newswire via SeaPRwire.com) - On March 24, 2025, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2024 annual results. In 2024, facing numerous challenges brought about by a complex environment, the Group adhered to long-termism, actively promoted high-quality development, continuously optimized its product structure, actively advanced innovation and upgrading, strengthened channel construction, and accurately captured consumption trends, and achieved steady growth in various financial indicators. For the twelve months ended December 31, 2024, the Group’s revenue grew 0.3% year-on-year to RMB80.651 billion. Among these, the revenue from Instant Noodles was RMB28.414 billion, while the revenue from Beverages was RMB51.621 billion. Gross profit margin improved by 2.7 percentage points year-on-year to 33.1%. EBITDA grew 17.3% year-on-year to RMB9.628 billion. The board of directors proposed to distribute a final dividend of RMB33.14 cents per common share and a special dividend of RMB33.14 cents per common share. The dividend payout ratio for the year reached 100%.Financial Summary For the twelve months ended 31 December RMB’00020242023ChangeRevenue80,650,91480,418,075↑ 0.3%Gross margin33.1%30.4%↑ 2.7 ppt.Gross profit of the Group26,695,64324,467,089↑ 9.1%EBITDA9,627,8028,206,526↑ 17.3%Profit for the period4,322,1353,516,667↑ 22.9%Profit attributable to owners of the Company3,734,4293,117,461↑ 19.8%Earnings per share (RMB cents) Basic66.2855.33↑ 10.95centsDiluted66.2855.31↑ 10.97centsAs at 31 December 2024, cash at bank and on hand (including long-term time deposits) was RMB16,002.668 million, representing an increase of RMB1,264.287 million when compared to 31 December 2023. Gearing ratio was -19.3%.In 2024, China’s economy maintained steady growth. with GDP growing by 5.0% YoY, and the CPI increasing slightly by 0.2%. Against this macro-economic backdrop, consumer behaviour patterns changed, showing a more cautious and rational consumption tendency. Their attention to emotional value, health, green environmental protection, quality and cost effectiveness increased significantly. At the same time, shopping channels kept evolving, with offline hypermarkets declining, warehouse membership stores growing, and proximity-based small-format retail, including grocery stores and small supermarkets showing considerable market growth potential. In the face of consumption changes and channel reforms, enterprises needed to gain precise insights into consumer demands, grasp channel development trends, innovate products tailored to consumer needs, capture market opportunities, and earn consumer trust. This enabled them to achieve steady growth and high-quality development in an intensely competitive market.In 2024, the gross profit of the Instant Noodles business improved steadily. The revenue from Instant Noodles business was RMB28.414 billion, declining by 1.3% year-on-year, accounting for 35.2% of the Group’s total revenue. During the year, due to favourable selling prices and raw material prices, the gross profit margin of Instant Noodles business grew 1.6 percentage points year-on-year to 28.6%, which offset the impact of revenue decline. As a result of the year-on-year increase in gross profit margin, the profit attributable to shareholders of the Company in the Instant Noodles segment grew 1.8% year-on-year to RMB2.045 billion. During the year, in an increasingly differentiated market environment, the Instant Noodle business continued to focus on its core products, driving upgrades and iterations, optimizing marketing strategies, and gradually improving the gross profit structure. Through cooperation with reputable IP/brand ambassadors, the business launched the "brand vehicle" mobile marketing model, engaging directly with young consumer groups in high-traffic areas such as campuses. These efforts significantly enhanced brand awareness and influence. In addition, efforts were made to stay on top of transforming consumer shopping habits and seize the emerging channels opportunities. At the same time, adhering to aerospace quality as the benchmark, the Group introduced advanced aerospace food technology, becoming the first enterprise in the instant noodles industry to obtain the patent for aerospace application. This further consolidated and demonstrated the product quality advantages and technological strength, playing a leading role in driving high-quality industry development.In 2024, The overall revenue from Beverage business was RMB51.621 billion, with a year-on-year growth of 1.3%, accounting for 64.0% of the Group’s total revenue. During the year, benefiting from favourable product pricing strategies, the gross profit margin of Beverage business grew 3.2 percentage points year-on-year to 35.3%. As a result of the increase in gross profit margin, the profit attributable to the shareholders of the Company in the Beverage segment grew 52.3% year-on-year to RMB1.919 billion. During the year, the Beverage business focused on building scale advantages. It continued to consolidate its core categories while strategically expanding into new ones. By carefully introducing sugar-free products, it aimed to meet consumer demand for health and functional benefits while actively broadening its product range. Through a series of measures including optimizing category management, expanding emerging channels, improving distribution service quality, implementing precise cost control, increasing capital turnover efficiency, and enhancing supply chain effectiveness, the Group remained committed to improving operational efficiency and driving steady development and sustainable growth.Mr. Richard Chen, Chief Executive Officer, commented, “In 2025, the core driving force for China's economic growth is expected to rely on domestic demand. The Group will always adhere to the development strategy of “Consolidate, Reform and Develop”, continue to deeply cultivate its main business, deepen its sustainable development, and strive to achieve high-quality development. The Group will continue to increase investment in product innovation, brand building, and channel expansion, accurately capture market trends, establish an innovation mechanism oriented towards consumer needs, and further deepen the emotional connection between the brand and consumers. With precise market insights and well-planned channel strategies, it will continuously optimize channel efficiency and service quality. At the same time, it will actively promote lean procurement management and significantly improve intelligent management levels through the comprehensive application of digitalization and AI technologies. We will adhere to the concept of sustainable development, actively fulfil social responsibilities, strive to provide high-quality services to customers, create long-term value for consumers, achieve sustainable and substantial returns for shareholders, and build Tingyi into a National Brand that is trusted by the government, creates win-win partnerships, and is widely recognized and favoured by consumers.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.Investor Enquiries:Investor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 碧瑤綠色集團有限公司（「碧瑤」或「集團」；股份編號：01397.HK）欣然宣佈截至2024年12月31日止年度（「年內」）之全年業績。年內，集團收益為約26.0億港元，較去年增加約11.8%。集團年內純利約為56.5百萬港元，較2023年同比增加約17.3%。董事會建議派付本年度的末期股息每股3.8港仙。業務回顧及展望年內，清潔作為集團的核心業務，繼續於年內錄得增長，收益相比去年同期增加14.2%，至約2,086.8百萬港元，佔集團總收益約80.1%。集團為政府轄下的街道清潔服務版圖，覆蓋全香港共七區，服務人口約280萬，標誌碧瑤於香港清潔服務市場的領導地位。年內，集團的機動掃街車潔淨服務覆蓋香港各大區域。另外，集團亦為全港各大區的政府街市、設施及康樂場地提供清潔服務。此外，集團的其他清潔場地遍及各大醫院、政府診所、香港國際機場、學校、屋苑及私人機構等眾多不同場所，顯示集團的專業服務廣受認可。廢物管理及回收業務於年內收益錄得增長，相比去年同期增加約2.5%，至約285.8百萬港元，佔集團總收益約11.0%。廢物管理回收業務的毛利大幅增加約58.2%，至約33.5百萬港元，主要受惠於政府積極推動回收，大幅擴展包括廚餘的回收點網絡，便利市民參與並有效刺激收集量。集團繼續為政府轄下的五區提供廢物收集服務，服務人口約160萬。回收方面，集團作為環境保護署（「環保署」）服務承辦商，為香港數千個回收點提供收集服務（包括塑膠、玻璃樽、金屬、廢紙及廚餘），為市場領導者之一。集團於年內為公共場所及學校的回收箱，提供收集服務。碧瑤繼續為環保署的「塑膠回收先導計劃」服務合約，為香港區提供塑膠收集服務。此外，碧瑤亦為香港眾多環保署轄下的「綠在區區」回收環保站、回收便利點、智能回收機及不同機構，提供回收服務。另外，碧瑤為政府於香港多區負責玻璃容器收集及處理，以及廚餘收集，為市場領導者之一。綠色科技業務方面，集團積極發展綠色科技業務，通過結合智能數碼科技、大數據分析及物聯網技術，成功推出一站式智能回收系統。用戶通過實時數據準確掌握回收量，有助適時安排運輸、降低物流成本並減少碳排放。年內，集團贏得環保署兩份智能合約（分別提供智能廚餘回收機及智能磅），彰顯集團於綠色科技領域的產品創新、研發實力及市場領導地位，並支持香港邁向智慧城市的目標。現時集團綠色科技產品（如：智能回收機、智能廚餘回收機及智能磅等）於年內帶動集團的收入貢獻，已廣泛應用於政府機構、公營及私人住宅、商場、大學、醫院、大型展覽場館等，為市民提供便捷的回收體驗，提升回收效率，推動香港可持續發展進程。集團與怡和機器有限公司合作位於香港屯門環保園的生物炭工廠已於年內試營運，通過熱解技術將園林廢料轉化為高質量生物炭以作各種應用，從而達到「轉廢為材」的目的。園藝服務業務方面，集團客戶涵蓋大型私人住宅、政府處所、學校、商場、酒店、機場、香港房屋委員會、香港賽馬會、香港科學園、香港大學、香港科技大學及嶺南大學等各個類型。年內新中標的合約包括港深創新及科技園、油旺微型公園及東涌西新發展區。蟲害管理方面，集團年內繼續為黃大仙區及大埔區提供蟲害管理服務。此外，集團分別為古物古蹟辦事處轄下29個古蹟及華人廟宇委員會轄下24間廟宇，提供白蟻防治及監測服務。截至2024年12月31日，集團的手頭合約約38.9億港元，為日後年度，迎來可觀的收益。隨著以「市場主導模式」的塑膠飲料容器及紙包飲品盒生產者責任計劃有序實行，集團認為措施提供經濟誘因鼓勵市民積極參與回收，預計刺激塑膠飲料容器、紙包飲品盒回收率，促進回收行業健康發展，協助香港構建循環經濟及綠色產業。此外，集團於本財政年後贏得食物環境衞生署（「食環署」）供應太陽能智能廢物收集箱的服務合約。根據政府資料，食環署計劃於2026年底前在約300個地點增設多種廢物收集設施，包括太陽能廢物壓縮箱，進一步優化鄉郊地區廢物收集及改善環境衞生。集團的產品以可持續發展及智慧科技為設計理念，專為香港不同場景而研發，旨在提升收集質量、支持智慧城市建設、塑造宜居環境。隨著香港聯合交易所有限公司要求上市公司加強氣候相關揭露，相信市場對集團有關ESG的業務將與日俱增。展望未來，集團將在鞏固核心業務市場份額的同時，加快在香港及國際市場的擴展步伐，並適時探索併購、合營及新業務機會，推動業務增長，為股東創造長遠價值。有關集團2024年度業績公告詳情，請瀏覽以下網址：https://www.baguio.com.hk/zh-hant/investor/notices/碧瑤綠色集團簡介：碧瑤綠色集團（股份編號：01397.HK）成立於 1980 年，為香港最大的綜合環境管理方案供應商之一，提供環衞保潔、資源回收、循環再造、廢物管理、綠色科技、綠色產品、園藝綠化工程及害蟲防治等。集團應用最新科技，提供創新環境解決方案，為不同領域的客戶提供服務，包括政府部門、各大機構及跨國企業。集團努力不懈地提升環境、社會及管治(ESG)的表現，以推進集團的可持續發展，為了更綠的明天，實現將香港推動成為更清潔、更綠色、更健康城市的願景。如有垂詢，請聯絡：碧瑤綠色集團有限公司 投資者關係部電話: (852)2541 3388 電郵: ir@baguio.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月28日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽宣佈，其碳減排目標已正式通過「科學基礎減量目標倡議」（Science Based Target initiative或SBTi）認證，這一成果彰顯了周大福人壽對碳減排的決心，並為公司持份者提供了一套可衡量的標準，以監測公司在這方面的持續努力。去年十月，周大福人壽制定與《巴黎協定》一致的科學基礎目標，並成為首家主要在大灣區營運的「銀行、多元化金融、保險業」界別的機構向SBTi提交碳減排承諾書，牽頭推動可持續發展。SBTi是一個全球性的企業氣候行動組織，旨在協助企業在應對氣候危機方面發揮應有作用。周大福人壽的目標是在2029財年，將範圍1和範圍2的溫室氣體排放量減少37.8%（以2023財年水平為基準）。此外，就範圍3的投資組合目標，周大福人壽承諾到2029財年：- 將其上市股票和公司債券投資組合中的電力行業的每兆瓦時溫室氣體排放量減少59%（以2023財年水平為基準），- 在其上市股票和公司債券投資組合中，將至少44.8%（以投資價值計算）投資於已制定SBTi認證目標的公司。以上兩項舉措將涵蓋其總投資和貸款資產的65%。周大福人壽執行董事兼行政總裁葉文傑表示：「周大福人壽深明氣候行動不僅是一項重大責任，更有助於推動意義深遠的變革。我們一直與周大福創建緊密合作，以確保一致實現2050年淨零排放目標。此次碳減排目標獲得認證，充分體現了我們在減少營運和投資組合排放量的堅定決心。這一里程碑再次證明了我們致力於建設可持續未來，同時為持份者開創保險新價值。」周大福人壽將透過以下策略和行動，實現其碳減排目標：範圍1和範圍2營運碳減排措施：- 電動車轉型：將現有的租賃或自有車隊替換為電動車。- 提升能源效率：探索提高公司各辦公室的能源效率的機會。- 購買可再生能源證書：在優先推動電動車轉型和提升能源效率的同時，周大福人壽亦將研究從本地能源供應商購買可再生能源或可再生能源證書，或為同一市場內沒有其他選項的前提下，從亞洲及其他海外市場購買國際可再生能源證書，以進一步減少範圍2的剩餘營運排放。降低範圍3中15個類別排放的措施：- 積極擁有權（Active Ownership）與參與策略：分階段實施參與策略，以促進實際減排。- 氣候融資：探索與環境、社會及企業管治（ESG）相關的產品及氣候融資機會。- 策略與治理：建立完善的管治架構，以推動氣候行動。- 政策與倡導：尋求機會建立合作與夥伴關係，以擴大影響力。周大福人壽選擇上述碳減排措施，是因為這些措施預計將對公司的氣候轉型產生最直接的影響。截至2024 年6 月，公司投資組合的碳足跡已較2023年同期的基數減少了超過15%。此外，公司已投資超過35 億港元於獲ESG 標籤的債券及減碳基金，主要聚焦亞洲市場，以支持區內綠色經濟轉型。關於周大福人壽保險有限公司周大福人壽保險有限公司（「周大福人壽」）扎根香港40年，為周大福創建有限公司（「周大福創建」）（香港股份代號：659）的全資附屬公司，也是香港最具規模的壽險公司之一。作為周大福企業成員，周大福人壽緊扣鄭氏家族（「周大福集團」或「集團」）多元業務體系的雄厚資源，致力為客戶及其摯愛家人於「生活、成長、健康、傳承」的人生旅程中，提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局，周大福人壽矢志成為亞太區領先的保險公司，持續開創保險新價值。傳媒聯絡周大福人壽保險有限公司品牌發展及傳訊部陳佳容+852 2591 8504deronie.tan@ctflife.com.hk 周大福人壽保險有限公司（於百慕達註冊成立之有限公司） Copyright 2025 亞太商訊 via SeaPRwire.com.